Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including complex robotic surgery, clinical trials and novel therapeutics such as precision medicine, CAR T-Cell Therapy and other forms of immunotherapy.
$2 Million in Grants Drives Scientific Exploration of Rare Blood Cancer
With 20 percent of pediatric patients and up to 50 percent of adult patients with T-cell acute lymphoblastic leukemia suffering relapse, there is a need to discover novel therapeutic targets to more effectively treat this population. More than $2 million in grants recently awarded to Rutgers Cancer Institute of New Jersey resident researcherDaniel Herranz Benito, PhD, assistant professor of pharmacology at Rutgers Robert Wood Johnson Medical School, will support examination of potential treatment targets for T-cell acute lymphoblastic leukemia. Learn more
Rutgers Cancer Institute Doctors Named ‘Tops’ in Oncology Care
Several physicians from Rutgers Cancer Institute of New Jersey have been named among ‘New Jersey’s Top Doctors in Cancer Care’ by Castle Connolly Medical Ltd., which publishes resource guides on top healthcare professionals across the nation. The listing appeared recently in Jersey’s Best magazine. A physician-led research team assembled by Castle Connolly collected peer surveys that highlighted various career aspects. Training, board certification, clinical skills, years in practice, leadership posts and other criteria were analyzed.Learn who made the list
Identifying New Prognostic Markers for Childhood Hodgkin Lymphoma
Rutgers Cancer Institute of New Jersey pediatric hematologist/ oncologist Scott Moerdler, MD, assistant professor of pediatrics at Rutgers Robert Wood Johnson Medical School, has received a $50,000 grant to help identify new prognostic markers and potential therapeutic targets in pediatric Hodgkin lymphoma. The Children’s Oncology Group Foundation awarded this grant with the underlying support of St. Baldrick’s Foundation. An aim of the project is to leverage the findings to support new clinical trials for pediatric patients with Hodgkin lymphoma.Learn more
Striking Out Against Cancer
Taking the mound at a recent New York Yankees game, Rutgers Cancer Institute of New Jersey Director Steven K. Libutti, MD, FACS, who is also senior vice president of Oncology Services for RWJBarnabas Health, tossed a first pitch in recognition of all those battling cancer as well as honoring cancer survivors. “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute in partnership with RWJBarnabas Health are committed to easing the cancer burden in our state, as well as beyond our borders. We thank the New York Yankees organization and WFAN sports radio for this opportunity to raise awareness and hope,” shares Dr. Libutti.